Evaluation of immune response and protective effect of four vaccines against the tick-borne encephalitis virus

Морозова, О. В.; Бахвалова, В. Н.; Potapova, O. F.; Гришечкин, А. Е.; Исаева, Е. И.; Aldarov, K.V.; Klinov, Dmitry V.; Vorovich, M. F.

doi:10.1016/j.vaccine.2014.02.046

Cited by 31 publications

(28 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, of 12 heterologous strains reported in the present paper, 5 were identified more than 40 y ago, while only one (Kolarovo-2008) was isolated less than 10 y ago. This has been emphasized, 39 since Zausaev-like Siberian strains have prevailed in Russia in recent years, but no human studies on the immunogenicity provided by the inactivated vaccines against these strains have been conducted. In their murine model, Morozova et al 39 .…”

Section: Discussionmentioning

confidence: 99%

“…This has been emphasized, 39 since Zausaev-like Siberian strains have prevailed in Russia in recent years, but no human studies on the immunogenicity provided by the inactivated vaccines against these strains have been conducted. In their murine model, Morozova et al 39 . documented only partial protection of all inactivated vaccines against the Siberian strain 2086 isolated in 2010.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: Systematic review and meta-analysis

Domnich

Panatto

Arbuzova

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Tick-borne encephalitis (TBE) virus, which is usually divided into European, Far Eastern and Siberian subtypes, is a serious public health problem in several European and Asian countries. Vaccination is the most effective measure to prevent TBE; cross-subtype protection elicited by the TBE vaccines is biologically plausible since all TBE virus subtypes are closely related. This manuscript systematically explores available data on the cross-subtype immunogenicity elicited by the currently available Western vaccines based on the European subtype. Completed immunization course of 3 doses of both Western vaccines determined very high seroconversion/seropositivity rates against both Far Eastern and Siberian subtypes among previously flavivirus-naïve subjects. All but one study found no statistically significant difference in titers of neutralizing antibodies against strains belonging to homologous and heterologous subtypes. Pooled analysis of randomized controlled trials on head-to-head comparison of immunogenicity of Western and Russian TBE vaccines did not reveal differences in seroconversion rates against Far Eastern isolates in either hemagglutination inhibition (risk ratio = 0.98, p = 0.83) or enzyme-linked immunosorbent (risk ratio = 0.95, p = 0.44) assays after 2 vaccine doses. This suggests that, in regions where a heterogeneous TBE virus population circulates, vaccines based on the European subtype may be used alongside vaccines based on the Far Eastern subtype. Studies on the field effectiveness of TBE vaccines and investigation of vaccination failures, especially in countries where different subtypes co-circulate, will further elucidate TBE vaccination-induced cross-subtype protection.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: Systematic review and meta-analysis

Domnich

Panatto

Arbuzova

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Схема вакцинации "Клещ-Э-Вак" "ЭнцеВир" Ранее изучение реактогенности и иммуногенности цельновирионных концентрированных инактивированных вакцин против КЭ проводилось неоднократно [10][11][12][13][14][15][16], однако в большинстве этих исследований представлены данные испытания вакцин при использовании либо только стандартной [12][13][14], либо экстренной [15,16] схемы введения препаратов. Данные сравнительного изучения стандартной и экстренной схем по показателям реактогенности и иммуногенности в одном эксперименте при вакцинации одной и той же серией вакцины против КЭ крайне ограничены [17,18].…”

Section: суммарные местные и общие реакции у реципиентов вакцины «клеunclassified

Immunogenicity and safety of the adult tbe vaccine «tick-e-vac»

Vorovich

Майкова

Chernokhaeva

et al. 2017

Problems of Virology

View full text Add to dashboard Cite

About 3,000 cases of TBE are registered annually in the Russian Federation. Vaccination is the main way to prevent the tick-borne encephalitis disease. Comparative study of the reactogenicity and immunogenicity of a new vaccine «Tick-E-Vac» was held. Volunteers aged from 16 years old were twice immunized with the vaccines «Tick-E-Vac» or «Encevir» derived from strains of Far East subtype of TBE virus, according to standard and emergency schemes. The clinical study was randomized, comparative, blind, and controlled. The frequency, intensity, time of occurrence, and duration of local and general reactions had been recorded. The titers of antiviral antibodies in ELISA had been determined to assess the immunological efficacy of vaccination. According to the results of the clinical study, the severity of local and general reactions in initial seronegative recipients was weak or moderate. The symptoms were usually manifested within 1-2 days after injection and persisted for not more than 4 days, after which time the symptoms disappeared. There was no statistically significant difference in the reactogenicity of the vaccines after the first and after the second injection. The reactogenicity also did not depend on the gender of recipients. After the first immunization, the level of seroprotection was not less than 43%; the average geometric titer of antibodies (GTA), not less than 1:200. After the second injection, the level of seroprotection reached 90-100%; GTA, not less than 1:500. The data on the reactogenicity and immunogenicity to the original seropositive recipients is not significantly different from the data for the initial seronegative recipients. The data indicate weak reactogenicity of the vaccines «Tick-E-Vac» and «Encevir». Double vaccination with an interval of 14 or 30 days leads to the formation of expressed immune response. Thus, differences in the level of seroprotection and in antiviral titers in the cases of the standard and emergency vaccination schedules are not statistically significant. The correlation between the development in recipients of local and general symptoms and the immunological efficacy of the vaccines has not been identified.

show abstract

“…Для вакцинации против КЭ широко используют четыре типа инактивированных вакцин, производимых в России (штаммы 205 и Софьин), Австрии (Neudorfl) и Германии (K23) (Leonova et al, 2007;Morozova et al, 2014). На тер-ритории Китая c 1953 г. применяют оригинальную инакти-вированную вакцину против ВКЭ на основе штамма ZenZhang (Yoshii et al, 2017).…”

unclassified

Candidate vaccine construction against tick-born encephalitis based on hybrid recombinant flagG-protE-protein

Belavin¹,

Кунык²,

Протопопова³

et al. 2017

Vestn. VOGiS

View full text Add to dashboard Cite

The present work describes the construction of the gene encoding the recombinant protein flagGprotE, its synthesis, purification and study. The recombinant flagGprotE protein is a promising molecule for deve loping a candidate recombinant vaccine against tick borne encephalitis by the ability to bind to mono clonal antibodies (MCA) against native protein E of tickborne encephalitis virus. The antigenic determi nants of two recombinant proteins were studied: protE and flagGprotE using a panel of 8 MCA. The recombinant protein protE comprises the tickborne encephalitis virus envelope protein and the flagG protE recombinant protein has an additional flagG domain encoding flagellin G of Salmonella typhi. It was found that the MCA tested revealed epitopes on the recombinant protein protE. This indicates that the investigated recombinant protein has an antigenic structure similar to the antigenic structure of the native tickborne encephalitis virus protein E. In the study of the recombinant protein flagGprotE by the ability to bind a panel of 8 MCA, only five of them react with epitopes of the tested protein. MCA 4F6, 7F10, and 6B9 did not recognize the corresponding epitope in the recombinant flagGprotE protein, while in the recombinant protein protE, these epitopes were detected successfully. Our data indicate that the anti genic structure of recombinant protEprotein can be changed under the influence of the flagellin domain, which in turn can lead to the unavailability of some antigenic determinants. This fact must be taken into account when constructing recombinant molecules with antigenic properties. Nevertheless, the funda mentally important regions in the region of the fusion peptide and III domain are antigenically present on the surface of the recombinant protein. This should ensure the formation of neutralizing antibodies, and the pres ence of a complete amino acid sequence of protein E in the recombinant protein induces the formation of a Tcell immune response. The emergence of a new generation of vaccines against tickborne encephalitis В настоящей работе описаны конструирование гена, кодирующего гибридный белок flagGprotE, синтез и очистка полученного реком бинантного белка, а также исследование его антигенных характе ристик на панели моноклональных антител (МКА). Рекомбинант ный белок flagGprotE является перспективной молекулой для создания кандидатной рекомбинантной вакцины против клещево го энцефалита благодаря способности к связыванию с МКА против природного белка Е вируса клещевого энцефалита. Проведено ис следование антигенных детерминант двух рекомбинантных бел ков protE и flagGprotE с помощью панели из восьми МКА. Реком бинантный белок protE представлен белком оболочки вируса кле щевого энцефалита, в рекомбинантном белке flagGprotE к нему добавлен домен flagG, кодирующий флагеллин G Salmonella typhi. Установлено, что изучаемые МКА связывались с эпитопами ре комбинантного белка protE. Это свидетельствует о том, что иссле дуемый рекомбинантный белок имеет антигенную структуру, схо жую с антигенной ст...

show abstract

Evaluation of immune response and protective effect of four vaccines against the tick-borne encephalitis virus

Cited by 31 publications

References 16 publications

Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: Systematic review and meta-analysis

Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: Systematic review and meta-analysis

Immunogenicity and safety of the adult tbe vaccine «tick-e-vac»

Candidate vaccine construction against tick-born encephalitis based on hybrid recombinant flagG-protE-protein

Contact Info

Product

Resources

About